IFPMA expresses its disappointment at the decision to consider an extension of a waiver of intellectual property rights on COVID-19 therapeutics and diagnostics taken by Member States at the World Trade Organization (WTO).
Read moreWe welcome the adoption at the 15th meeting of the Conference of the Parties to the UN Convention on Biological Diversity (COP15) of a framework that addresses biodiversity loss across the globe.
Read moreToday, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) announced Sunao Manabe, President and Chief Executive Officer (CEO) at Daiichi Sankyo, as IFPMA Vice President. IFPMA President and CEO of UCB, Jean-Christophe Tellier welcomes Sunao Manabe, President and CEO of Daiichi Sankyo to IFPMA leadership team. “I am thrilled Sunao will join IFPMA’s leadership team,”...
Read more
Immunization is the greatest success story of the twentieth century. Vaccines eliminated most of the childhood diseases that used to cause millions of deaths, making possible a life without disabilities caused by certain communicable diseases like polio for the first time in human history.
Read more
Ever since the smallpox vaccine discovery over two centuries ago, vaccines have successfully worked to eradicate, eliminate, or control many infectious diseases.
Read more
Ann-Lise Mikolajczak, Manager, Global Health and Access at IFPMA and Luca Deplano, Associate Manager, Innovation and Access Policy at IFPMA, joined Ryculture Health and Social Innovation’s 2nd Annual YouTH Voices Summit, focused on activating youthful leadership toward the realization of universal health coverage.
Read more
IFPMA statement on behalf of the pharmaceutical industry at the Convention on Biological Diversity (CBD) COP 15 meeting regarding Digital Sequence Information.
Read moreDuring the World Health Organization (WHO) Third Meeting of the Intergovernmental Negotiating Body, IFPMA delivered four messages.
Read moreAs WTO Member States continue to discuss an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics, latest evidence and data published today explains what the consequences of such a waiver would have on industry’s ability to fight the COVID-19 pandemic.
Read more
New annual research conducted by Ipsos UK, shows that the research-based pharmaceutical industry has garnered a positive reputation, with its pandemic response and the impact of its innovations seen as key strengths by the general public.
Read moreThe Japanese Pharmaceutical Manufacturers Association (JPMA) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) jointly submitted the “Proposals from the Pharmaceutical Industry for the G7 Hiroshima Summit Health Agenda” to the Prime Minister, Minister of Health, Labor and Welfare, Minister of Finance, and Minister of Foreign Affairs.
Read moreThe pace of resistance to existing antibiotics is outpacing the rate at which new ones can reach the market and be used against difficult-to-treat infections.
Read more